SEIZE THE $50 BILLION SITE-OF-CARE SHIFT OPPORTUNITY
Get the tools, data, and insights to drive growth.
Learn more
RECALIBRATE YOUR HEALTHCARE STRATEGY
Learn 4 strategic pivots for 2025 and beyond.
Learn more

Daily Briefing

AI Roundup: Can ChatGPT beat surgeons at explaining the risks and benefits of surgery?


Surgeons vs. ChatGPT: Who better explains the risks and benefits of surgery? For a new study, researchers at the University of California, San Francisco, explored whether ChatGPT can write effective "informed consent" forms to explain the risks, benefits, and alternatives (RBAs) of common surgeries. In a head-to-head comparison of 36 RBAs, ChatGPT’'s writing was measured at a lower (and thus more accessible) grade level, while its descriptions of benefits and alternatives were judged to be more complete and accurate.

Implications: Despite the hype about using large language models (LLMs) to diagnose and treat disease, LLMs are fundamentally trained on language—so it’s not surprising they excel at expressing complex information in easy-to-understand terms. I wouldn’t be surprised if LLMs transform how doctors talk to patients before they revolutionize treatments.

"The shape of the shadow of the thing." Ethan Mollick, a professor at The Wharton School, is one of the most consistently provocative thinkers on how businesses can do real work with generative AI. In a recent post, he pauses to reflect on a transitional moment in AI's development, as we pass the initial hype wave and begin incorporating AI into our workdays: What is this "thing" we call AI, anyway? Which of its limits are transient, and which are fundamental? And what will AI turn into as it grows ever-more powerful?

A new AI tool can diagnose brain tumor subtypes in just 90 minutes. Researchers in the Netherlands announced new deep-learning algorithm that can quickly diagnose brain cancer subtypes from fragments of a tumor's DNA. Using the tool, surgeons can sample a tumor at the start of surgery and, while the patient is still on the operating table, update their surgical plan to target the patient's specific cancer. The algorithm's ability to recognize shreds of DNA is "akin," the New York Times reports, "to someone recognizing an image based on only one percent of its pixels, and from an unknown portion of the image."

The Atlantic's deep dive into OpenAI CEO Sam Altman. I can't beat The Atlantic's copywriters, who tease this piece as covering Altman's "ambitious, ingenious, terrifying quest to create a new form of intelligence." If you're a regular reader of AI news, you won't find much new here: It includes a 101-level explainer of ChatGPT's technology, a rundown of Altman's interactions with world leaders, and some existential dread about AI's long-run implications. But few articles have so effectively captured Altman's blend of hubris, humility, and humanity — illuminating a personality that, for better and worse, is changing our world fast.

AI peers inside 2,000-year-old scrolls buried by Vesuvius. This one has nothing to do with healthcare, but it's just so cool. Spurred by a $1 million prize, computer scientists are making fast progress at using machine learning to read papyri buried in the ancient eruption of Mount Vesuvius. The scrolls are so delicate they crumble if unrolled, and their ink is all but invisible — so competitors must work from 3D scans of unopened scrolls taken in a particle accelerator. If successful, the effort could double humanity's corpus of text from antiquity. (In case you're wondering, the first word deciphered was "ΠΟΡΦΥΡΑϹ," which means "purple.")


SPONSORED BY

INTENDED AUDIENCE

AFTER YOU READ THIS

AUTHORS

Thomas Seay

Managing director

TOPICS

INDUSTRY SECTORS

Related Resources

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.